The Samyang Biopharm's pharmaceutical plant was established in 1997 to produce premium quality active pharmaceutical ingredients(APIs) using novel plant cell culture and semi-synthetic technologies. The plant was equipped in 2007 with modern injection filling line which is dedicated to produce anti-cancer injectables. The Biopharmaceutical plant is Korean GMP compliant and passed inspection of German and Japanese health agencies as well.
